T2 Biosystems Announces Fourth Quarter and Full Year 2022 Financial Results
March 13, 2023 16:05 ET
|
T2 Biosystems, Inc.
LEXINGTON, Mass., March 13, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes,...
T2 Biosystems to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023
March 03, 2023 08:00 ET
|
T2 Biosystems, Inc.
LEXINGTON, Mass., March 03, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today...
T2 Biosystems Announces Pricing of $12 Million Public Offering
February 15, 2023 07:30 ET
|
T2 Biosystems, Inc.
LEXINGTON, Mass., Feb. 15, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) today announced the pricing of its previously announced underwritten public offering of 11,111,111 shares of...
T2 Biosystems Announces Proposed Public Offering
February 13, 2023 16:19 ET
|
T2 Biosystems, Inc.
LEXINGTON, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) today announced that it is commencing an underwritten public offering of shares of its common stock (or common...
T2 Biosystems Announces Positive Results upon Completion of U.S. Clinical Evaluation for the T2Biothreat Panel
February 13, 2023 16:01 ET
|
T2 Biosystems, Inc.
LEXINGTON, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced...
T2 Biosystems Advances to the Phase 2 in HHS and the Steven and Alexandra Cohen Foundation’s LymeX Diagnostics Prize
February 06, 2023 16:05 ET
|
T2 Biosystems, Inc.
LEXINGTON, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today...
T2 Biosystems Reports Granting of Inducement Award
February 03, 2023 16:30 ET
|
T2 Biosystems, Inc.
LEXINGTON, Mass., Feb. 03, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens, and antibiotic resistance genes, announced today...
T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results
January 23, 2023 16:30 ET
|
T2 Biosystems, Inc.
LEXINGTON, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced...
T2 Biosystems Announces Extension of Multiyear Innovative Technology Contract with Vizient, Inc.
December 28, 2022 09:00 ET
|
T2 Biosystems, Inc.
LEXINGTON, Mass., Dec. 28, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced...
T2 Biosystems Highlights Peer-Reviewed Article Linking COVID-19 and Sepsis and Underscoring CDC Call for Adoption of Early and Accurate Microbial Diagnosis to Guide Targeted Initial Antimicrobial Therapy
December 08, 2022 08:28 ET
|
T2 Biosystems, Inc.
LEXINGTON, Mass., Dec. 08, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the...